Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago

Baricitinib

Immunosuppressant Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Rheumatoid Arthritis

Baricitinib tablet is used to treat adults with moderate to severely active Rheumatoid Arthritis who haven't responded well enough to one or more tumor necrosis factor (TNF) antagonist therapies. There is one limit on its use. Baricitinib is not recommended together with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as Azathioprine and cyclosporine.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. Janus kinases (JAKs) are enzymes that pass signals from receptors on the cell surface into the cell. These signals come from a number of cytokines and growth factors that are involved in haematopoiesis, inflammation and immune function. Inside the cell, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), and the STATs then switch on gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting the enzymatic activity of JAK1 and JAK2, so the phosphorylation and activation of STATs is reduced.

Pregnancy & Breastfeeding

Baricitinib must not be used during pregnancy. As for breastfeeding, there is no information on whether baricitinib passes into human milk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The recommended adult dose of Baricitinib is 2 mg once daily. You can use it on its own or together with Methotrexate or other Disease-modifying antirheumatic drugs (DMARDS). Baricitinib can be taken by mouth, with or without food. Pediatric use: The safety and effectiveness of Baricitinib in pediatric patients have not been established. Geriatric use: Elderly patients are more likely to have decreased renal function, so care should be taken when choosing the dose. Hepatic impairment: No dose adjustment is needed in patients with mild or moderate hepatic impairment. Renal impairment: Baricitinib is not recommended for patients with an estimated GFR of less than 60 mL/min/I .73 m2.